FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Hims & Hers Super Bowl Ad Hit

[ Price : $8.95]

The Institute for Safe Medicines calls on FDA, the Federal Trade Commission, and the Department of Justice to take enforcement act...

FDA DTC Ad Crackdown Raises Legal Issues: Attorneys

[ Price : $8.95]

Five Sidley attorneys recommend ways in which drug companies can analyze their direct-to-consumer promotions to see if they are li...

FDA Flags Safety Reporting Lapses at U.K. Clinical Trial Site

[ Price : $8.95]

FDA cites a U.K.-based clinical research center for failing to promptly report adverse events and for potential falsification of s...

Vertex Reports Positive Interim Phase 3 Data for Povetacicept

[ Price : $8.95]

Vertex Pharmaceuticals says an interim analysis of its Phase 3 RAINIER trial showed its experimental therapy povetacicept signific...

Capricors Duchenne Cell Therapy BLA Resubmitted

[ Price : $8.95]

FDA accepts for review a Capricor Therapeutics BLA resubmission for its experimental cell therapy deramiocel, intended to treat he...

FDA OKs Leucovorin for Ultra-Rare Brain Disorder, But Not Autism

[ Price : $8.95]

FDA approves an expanded use of GSKs Wellcovorin (leucovorin calcium) tablets for treating cerebral folate deficiency in adult and...

Xenon Reports Positive Phase 3 Data for Epilepsy Drug

[ Price : $8.95]

Xenon Pharmaceuticals says its experimental epilepsy drug azetukalner met the primary endpoint in a late-stage clinical trial in p...

Updated Guidance Clarifies Biosimilar Development Requirements

[ Price : $8.95]

FDA posts an updated draft guidance outlining new and revised recommendations for companies developing biosimilar products.

Incyte Gets Complete Response Over Catalent Inspection Issues

[ Price : $8.95]

FDA sends Incyte a complete response letter for its supplemental BLA for Zynyz (retifanlimab-dlwr) injection that cited inspectio...

Group urges Pfizer to Retract Threat on Drug Supplies

[ Price : $8.95]

Consumer advocacy group Public Citizen urges Pfizer to commit to maintaining access to its medicines in Europe after comments by C...